bioAffinity Technologies, Inc.

BIAF | $2.78 -4.47% -4.68% 140K

(0.0% 1d) (43.8% 1m) (53.3% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (9.62% volume)
Earnings Calendar:
Market Cap: $ 32,009,904

Sec Filling | Patents | 2022 employees

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

machine learning respiratory lung cancer diagnostics

add to watch list Paper trade email alert is off

Press-releases

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| -4.12% | O: -7.22% H: 0.0% C: -3.33%
lung initiative cancer for

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 38.12% | O: 2.97% H: 1.92% C: 0.48%
year financial results

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board
Published: 2024-02-06 (Crawled : 13:30) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 77.03% | O: -0.38% H: 0.64% C: -0.64%
lung network medical

bioAffinity Technologies In The News - January 30, 2024
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 74.38% | O: 2.5% H: 0.51% C: -2.44%

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer - January 23, 2024
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 84.77% | O: 5.3% H: 0.0% C: -2.52%
award patent cancer treatment

bioAffinity Technologies In the News
Published: 2024-01-08 (Crawled : 14:30) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 82.41% | O: 7.22% H: 0.0% C: -4.88%

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
Published: 2023-11-15 (Crawled : 14:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 93.62% | O: 0.6% H: 0.0% C: -2.39%
lung cancer

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-14 (Crawled : 00:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K

| 94.64% | O: -2.33% H: 7.14% C: 2.93%
business update financial results

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
Published: 2023-11-06 (Crawled : 14:30) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K